|
| 36127284 | Eribulin as first-line treatment in older patients with advanced breast cancer: A multicenter phase II trial [SAKK 25/14]. | J Geriatr Oncol | 2023 |
| 37550554 | Molecular characterization of breast cancer cell pools with normal or reduced ability to respond to progesterone: a study based on RNA-seq. | J Genet Eng Biotechnol | 2023 |
| 36635391 | Alternate-day dosing of pomalidomide in relapsed/ refractory multiple myeloma: a multicenter, single-arm phase 2 trial. | Leukemia | 2023 |
| 34930650 | Locally advanced breast cancer. | Breast | 2022 |
| 35576695 | Assessment of the management of carcinomatous meningitis from breast cancer globally: a study by the Breast International Group Brain Metastasis Task Force. | ESMO Open | 2022 |
| 35396243 | Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance. | BMJ Case Rep | 2022 |
| 35662713 | Clinical Implementation of <i>DPYD</i> Pharmacogenetic Testing to Prevent Early-Onset Fluoropyrimidine-Related Toxicity in Cancer Patients in Switzerland. | Front Pharmacol | 2022 |
| 33082214 | Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the SOLE Trial. | Clin Cancer Res | 2021 |
| 34384882 | Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. | Ann Oncol | 2021 |
| 34312396 | Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. | NPJ Breast Cancer | 2021 |
| 33232506 | Fluoropyrimidine chemotherapy: recommendations for DPYD genotyping and therapeutic drug monitoring of the Swiss Group of Pharmacogenomics and Personalised Therapy. | Swiss Med Wkly | 2020 |
| 31838077 | Evaluating the role of ENOSF1 and TYMS variants as predictors in fluoropyrimidine-related toxicities: An IPD meta-analysis. | Pharmacol Res | 2020 |
| 31949268 | Correction: Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. | Br J Cancer | 2020 |
| 30967649 | Quality of life under extended continuous versus intermittent adjuvant letrozole in lymph node-positive, early breast cancer patients: the SOLE randomised phase 3 trial. | Br J Cancer | 2019 |
| 31500588 | Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data. | BMC Cancer | 2019 |
| 31174485 | Characterization of molecular scores and gene expression signatures in primary breast cancer, local recurrences and brain metastases. | BMC Cancer | 2019 |
| 29092024 | Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. | Ann Oncol | 2018 |
| 30270111 | Letter comments on EJC published article: Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2-positive breast carcinomatous meningitis. | Eur J Cancer | 2018 |
| 29700818 | Angiosarcoma of the scalp responding to nivolumab: a case report. | Br J Dermatol | 2018 |
| 29443653 | Efficacy of Chemotherapy for ER-Negative and ER-Positive Isolated Locoregional Recurrence of Breast Cancer: Final Analysis of the CALOR Trial. | J Clin Oncol | 2018 |
| 29336323 | Nivolumab for recurrent cutaneous squamous cell carcinoma: three cases. | Eur J Dermatol | 2018 |
| 29158011 | Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. | Lancet Oncol | 2018 |
| 29198034 | Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study. | Virchows Arch | 2018 |
| 27001120 | The impact of ABCC11 polymorphisms on the risk of early-onset fluoropyrimidine toxicity. | Pharmacogenomics J | 2017 |
| 28139840 | Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity. | Clin Pharmacol Ther | 2017 |
| 28407750 | Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10). | BMC Cancer | 2017 |
| 28529311 | Spotlight on pomalidomide: could less be more? | Leukemia | 2017 |
| 28689204 | A Vexing CA 125 Raise in a Patient with Pleural Effusion and Ovarian Cancer. | Respiration | 2017 |
| 27663567 | Poor Prognosis After Second Locoregional Recurrences in the CALOR Trial. | Ann Surg Oncol | 2017 |
| 27998961 | Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99. | Ann Oncol | 2017 |
| 26837323 | [Male Breast Cancer: What is Different?]. | Praxis (Bern 1994) | 2016 |
| 26646758 | The effect of real-time electronic monitoring of patient-reported symptoms and clinical syndromes in outpatient workflow of medical oncologists: E-MOSAIC, a multicenter cluster-randomized phase III study (SAKK 95/06). | Ann Oncol | 2016 |
| 27498287 | Response to Pembrolizumab in a Patient with Relapsing Thymoma. | J Thorac Oncol | 2016 |
| 27311996 | A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing. | J Thorac Oncol | 2016 |
| 24923815 | Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity. | Int J Cancer | 2015 |
| 26599269 | Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy. | Oncol Res Treat | 2015 |
| 26244261 | Dihydropyrimidinase and β-ureidopropionase gene variation and severe fluoropyrimidine-related toxicity. | Pharmacogenomics | 2015 |
| 26313663 | Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). | Br J Cancer | 2015 |
| 26709490 | Successful AZD9291 Therapy Based on Circulating T790M. | J Thorac Oncol | 2015 |
| 26695558 | Brain metastases in gastro-oesophageal adenocarcinoma: insights into the role of the human epidermal growth factor receptor 2 (HER2). | Br J Cancer | 2015 |
| 25789838 | Rapid response to trastuzumab emtansine in a patient with HER2-driven lung cancer. | J Thorac Oncol | 2015 |
| 25593346 | Complement activation and rituximab distribution in CNS NHL--letter. | Clin Cancer Res | 2015 |
| 24487691 | Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences. | Breast Cancer Res Treat | 2014 |
| 25381395 | Maastricht Delphi consensus on event definitions for classification of recurrence in breast cancer research. | J Natl Cancer Inst | 2014 |
| 24767882 | First international consensus guidelines for breast cancer in young women (BCY1). | Breast | 2014 |
| 24439313 | Chemotherapy for isolated locoregional recurrence of breast cancer (CALOR): a randomised trial. | Lancet Oncol | 2014 |
| 23341482 | Reply to 'Staging for distant metastases in operable breast cancer: a suggested expansion of the ESMO guideline recommendation for staging imaging of node-negative, hormonal receptor-negative disease' by U. Gueth et al. | Ann Oncol | 2013 |
| 23918950 | Optimal sequence of tamoxifen and aromatase inhibitors to prevent bone loss. | J Clin Oncol | 2013 |
| 23584301 | A patient with lung adenocarcinoma and RET fusion treated with vandetanib. | J Thorac Oncol | 2013 |
| 21234609 | Adherence to ESMO clinical recommendations for prophylaxis of chemotherapy-induced nausea and vomiting. | Support Care Cancer | 2012 |